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ABSTRACT
Protein transfection is a versatile tool to study or manipulate cellular processes and also shows
great therapeutic potential. However, the repertoire of cost effective techniques for efficient and
minimally cytotoxic delivery remains limited. Mesoporous silica nanoparticles (MSNs) are multi-
functional nanocarriers for cellular delivery of a wide range of molecules, they are simple and
economical to synthesize and have shown great promise for protein delivery. In this work we
present a general strategy to optimize the delivery of active protein to the nucleus. We generated
a bimolecular Venus based optical sensor that exclusively detects active and bioavailable protein
for the performance of multi-parameter optimization of protein delivery. In conjunction with cell
viability tests we maximized MSN protein delivery and biocompatibility and achieved highly
efficient protein transfection rates of 80%. Using the sensor to measure live-cell protein delivery
kinetics, we observed heterogeneous timings within cell populations which could have a con-
founding effect on function studies. To address this problem we fused a split or dimerization
dependent protein of interest to chemically induced dimerization (CID) components, permitting
control over its activity following cellular delivery. Using the split Venus protein we directly show
that addition of a small molecule dimerizer causes synchronous activation of the delivered protein
across the entire cell population. This combination of cellular delivery and triggered activation
provides a defined starting point for functional studies and could be applied to other protein
transfection methods.
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Introduction
The cellular delivery of proteins is both a useful
method to study cell pathways and a promising
possibility for future medicine [1–4]. However, the
toolkit for cost-effective and highly functional in
vitro transfection remains limited, whilst chal-
lenges such as short protein serum half-life, ineffi-
cient cellular uptake and endosomal entrapment
hinder delivery in vivo. Thus, advancements in
protein delivery would be useful for cell research
and are required to remove a major barrier to the
implementation of potential therapies.
Mesoporous silica nanoparticles (MSNs) are a
versatile nanocarrier format that has been used for
the delivery of chemotherapeutic agents[5,6], oli-
gonucleotides[7,8], and proteins[9–11]. MSNs fea-
ture a stable framework to load and shelter cargo
from proteases and the immune system and com-
bine high cellular uptake efficiency with flexible
surface functionalisation. Diverse surface conjuga-
tions permit augmentation of the nanoparticles to
enable the modulation of serum half life, selective
cell targeting and controlled drug release[12–17].
MSNs can be generated in large volumes at low
financial and labor expenditure [18]. Having pre-
viously demonstrated the delivery of bioactive pro-
teins using our large pore MSN variant [19] we
sought to produce an optimized delivery protocol
that maximizes efficiency whilst retaining good
biocompatibility, i.e. the integrity and viability of
cells. Beside cellular uptake efficiency, the general
applicability of MSNs requires that delivered pro-
teins escape the endosomes and retain their func-
tion[20].
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Several techniques have been developed to
quantify efficiencies of cellular protein delivery.
The methods often exploit pre-existing cytoplasm
to endosome differences such as pH[21], enzyme
content[22], access to DNA[23], redox status[24–
26] or localization[27] and some utilize the physi-
cal separation of the compartments to create
exploitable distinctions between the two environ-
ments[28,29]. However, despite the advantages of
each of these methods, many of these techniques
do not provide a real-time readout, give a non-
linear output due to amplification, transcription or
recombination, give no indication of post-endo-
some protein functionality, rely on endpoint assays
on entire batches of cells, or require complex
image analysis. Quantifying delivery efficiencies
of functional proteins in real-time still remains
challenging. Recently, GFP-based bimolecular
fluorescence complementation (BiFC) assays have
been developed, consisting of two proteins derived
from genetic splitting of a fluorescent protein that
only fluoresce after complementation. BiFC assays
have been successfully employed for the compar-
ison of cell penetrating peptide (CPP) function
and the assessment of antibody internalization
[30–32]. They deliver a relative fluorescent readout
which is ideal for optimization processes.
In this work, we develop a Venus based optical
sensor and apply it to investigate and optimize in
vitro MSN mediated bioactive protein delivery. We
demonstrate how the sensor can be easily applied
in conjunction with cell viability assays to optimize
diverse aspects of delivery including; total protein
transfection, population transfection percentages,
cell-to-cell variation, biocompatibility and live-cell
delivery kinetics. We demonstrate that large cell-
to-cell variability can occur in the delivery of
bioactive proteins. As functional studies greatly
benefit from defined starting points, we aimed to
add another level of control to allow for synchro-




Tetraethyl orthosilicate (TEOS, Aldrich, ≥99%), (3-
glycidyloxypropyl) trimethoxysilane (GPTMS,
Fluka, ≥97%), cetyltrimethylammonium p-toluene-
sulfonate (CTATos, Sigma), triethanolamine (TEA,
Aldrich, 98%),magnesium sulfate anhydrous (99.9%,
Sigma), toluene anhydrous (Sigma), bi-distilled
water obtained from a Millipore system (Milli-Q
Academic A10). N(alpha),N(alpha)-bis(carboxy-
methyl)-L-lysine hydrate (NTA-lysine, Aldrich),
sodium carbonate (Sigma), sodium bicarbonate
(Sigma), nickel chloride hexahydrate (Riedel-de
Haen), tris(hydroxymethyl)-aminomethane (TRIS,
≥99%, ROTH), acetic acid (99% – 100%, ROTH),
thiazolyl blue tetrazolium bromide (MTT, ≥97.5%,
Sigma), dimethyl sulfoxide molecular (DMSO,
Applichem, biology grade), Dulbecco’s Modified
Eagle’s Medium (DMEM, Sigma), Dulbecco’s
Phosphate Buffered Saline (PBS, Sigma), FBS
Superior (Biochrom, S0615), Gentamycin solution
(SERVA, 50 mg/ml), trypsin-EDTA solution
(Sigma, T3924), Dulbecco’s Modified Eagle’s
Medium – phenol red free (DMEM, Gibco), ethanol
(EtOH, Aldrich, absolute).
Synthesis and functionalization of large pore
MSNs
Un-functionalized MSNs were synthesized using a
modification of a previously reported procedure
[33]. In brief, a mixture of TEA (0.49 g,
3.3 mmol), CTATos (2.73 g, 6 mmol) and H2O
(144 g, 8 mol) was vigorously stirred (1250 rpm) at
80°C in a 250 ml glass flask until the solution
became homogeneous. TEOS (20.83 g, 0.1 mol)
was then added and the solution was continuously
stirred (1250 rpm) at 80°C for another 2 h, after-
wards the synthesized particles can be observed as
whitening of the solution. The as-synthesized par-
ticles were collected by centrifugation (7000 × g,
15 min) and subsequently subjected to organic
template extraction. The organic template extrac-
tion was carried out by heating particles in an
ethanolic solution (150 mL) containing 3 g of
ammonium nitrate at 90 °C under reflux for 1 h
followed by a second reflux at 90 °C in a 2 M HCl/
ethanolic solution (150 mL) for 1 h. The un-func-
tionalized mesoporous silica nanoparticles (un-
MSNs) were collected by centrifugation
(7000 × g, 20 min) and were washed with water
and EtOH after each extraction step.
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To attach epoxy groups to the surface of the
MSNs, a post-synthetic grafting procedure was
performed. 500 mg of un-MSNs were de-hydrated
under reflux (130 °C) in 150 mL of toluene in the
presence of MgSO4 for 4 h. GPTMS (190 mg,
0.83 mmol, 10 mol% of total silica) was subse-
quently added to the toluene solution, and the
solution was stirred (500 rpm) at 130 °C for 2 h.
After the solution had cooled to room tempera-
ture, the toluene was removed by rotary evapora-
tor (77 mbar, 45 °C, 250 rpm). The resulting epoxy
group-modified MSNs (MSN-Epoxy) were washed
three times with 150 mL of EtOH and preserved in
50 mL of absolute EtOH. Centrifugation (7000 × g,
20 min) was used to collect particles after each
washing step.
MSN-Epoxy particles were then modified to yield
NTA-functionalized MSNs (MSN-NTA). 360 mg of
MSN-Epoxy and 200 mg (0.6 mmol) of NTA-lysine
were mixed in 10 ml of carbonate-bicarbonate buffer
(100 mM, pH 9) and the mixture was stirred at RT
overnight. The functionalized MSN-NTA particles
were washed three times with 100 mL of tris-acetate
(TA) buffer (pH 8) at RT and re-suspended in 36 mL
of EtOH. Centrifugation (7000 × g, 20 min) was used
to collect particles after each washing step. To immo-
bilize Ni2+ on the surface of MSN-NTAs, 5 mg of
MSN-NTA was dispersed in 5 ml of NiCl2 (50 mM in
H2O) and stirred at RT for 4 h. The un-bound Ni
2+
was washed out with H2O (three times with 5 mL)
and the particles were collected following centrifuga-
tion (17000 × g, 5 min). The final NTA-Ni complex
modified MSNs (MSN-Ni) were stored in 5 mL of
EtOH (MSN concentration: 1mg/mL) for further use.
Characterization of MSNs
Scanning electron microscopy (SEM) and scan-
ning-transmission electron microscopy (STEM)
were performed at 30 kV on a Helios NanoLab
G3 UC instrument (FEI, USA) with a detection
system containing a TLD detector and a STEM
ADF detector. A drop of EtOH diluted MSN sus-
pension was dried on a carbon-coated copper grid
at room temperature for several hours before
SEM/STEM observation. Dynamic light scattering
(DLS) measurements were performed on a
Malvern Zetasizer-Nano instrument equipped
with a 4 mW He-Ne laser (633 nm). Nitrogen
sorption analysis was performed on a
Quantachrome Instrument NOVA 4000e at 77 K.
Samples (15 – 20 mg) were degassed at 120 °C
under vacuum (10 mTorr) one day before mea-
surement. Pore size distribution curves were
obtained based on non-local density functional
theory (NLDFT) procedures provided by
Quantachrome, using the adsorption branch of
N2 on silica.
Plasmid construction and deposition
A previously described pCAG mammalian expres-
sion vector containing an IRES-Blasticidin selection
gene following the ORF was used for creation of the
pCAG-FKBP-VN-T2A-mRFP cassette[34] (Figure
1a). The protein expression vector pET28a was
used for FRB-VC-Histag expression (Figure 1b).
The Gibson assembly method was applied for all




FRB-VC was expressed in E. coli (BL21 strain) and
purified via affinity chromatography on a His-trap
column. Expression was induced through addition
of 0.5 mM of isopropyl beta-D-1-thiogalactopyra-
noside (IPTG, ROTH) and cells were further cul-
tured at 18 °C overnight. Cells were harvested and
lysed in PBS buffer containing 100 μg/ml of lyso-
zyme (Serva, Germany), 2 mM of phenylmethane-
sulfonyl fluoride (PMSF, sigma) and 25 μg/ml of
DNAse (Applichem, Germany) followed by soni-
cation (Branson® Sonifier; 16 × 8 sec, 20% ampli-
tude). Cell debris was collected by centrifugation
at 20000 × g for 30 min. Protein purification was
performed using a manufacturers 8 M Urea pur-
ification protocol (Amersham Biosciences[36])
including renaturation of the protein via FPLC
(Äkta Purifier Amersham Biosciences, GE
Healthcare, USA) on a 1 ml His-trap column
(GE Healthcare, USA). Elution was performed
using an increasing imidazole gradient rather
than the step-wise imidazole increase outlined in
the protocol. Eluted protein was desalted using the
PD-10 (GE Healthcare, USA) column and concen-
trated with an Amicon filter column (cut-off 10
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kDa, Merck Millipore, Germany). Purified protein
in PBS was aliquoted followed by shock-freezing
and storage at −80 °C.
FRB-VC protein loading to MSN-Ni
1 mg of MSN-Ni was mixed with 500 µg of FRB-
VC protein in 500 µl of PBS at 4 °C with shaking
(400 rpm) for 1.5 h. The resulting MSN-FRB-VC
complexes were collected by centrifugation
(3000 × g, 3 min), washed with PBS (1 mL per
wash) twice, and re-suspended in 100 µl of PBS.
Cell culture and stable cell line
HeLa Kyoto cells[37] (HeLa k, a modified HeLa
cell line characterized by little cell motility and
thus suitable for live cell time-lapse imaging)
were cultured in DMEM medium supplemented
with 10% FBS and gentamycin (50 µg/ml in cell
culture medium) under 5% CO2 at 37°C. To gen-
erate a cell line stably expressing the pCAG-FKBP-
VN-T2A-mRFP construct, pCAG-FKBP-VN-T2A-
mRFP was transfected into HeLa k cells using
Lipofectamine 3000 reagent (Invitrogen).
Blasticidin (10 µg/ml in cell culture medium) was
used to select cells between 48 h after transfection
and 3 weeks. Highly mRFP fluorescent cells were
then isolated via flow cytometry (FACS Aria II, BD
Biosciences) to produce a monoclonal cell line
(HeLa-FKBP-VN).
Intracellular protein delivery for MSN
concentration optimization
HeLa-FKBP-VN cells in DMEM culture medium
were seeded on either a 2-well ibiTreat slide (ibidi,
Germany) or a 6-well plate (Corning, USA) at 50%
confluency 12 h before the intracellular protein
delivery experiment. MSNs loaded with FRB-VC
proteins (MSN-FRB-VCs) in PBS were added to
cell culture in a serum free DMEM and incubated
with cells at 37 °C for 2 h. Afterwards, the residual
particles in the medium were washed out using
PBS (1.5 mL per well) followed by a short chlor-
oquine shock (0.5 mM in standard DMEM, 1.5 mL
per well in cell culture medium, RT, 5 min) to
trigger endosomal protein release. Cells were then
incubated in fresh cell culture medium (phenol red
free). All the assays (live cell imaging, FACS ana-
lysis and fluorescence readout) were performed at
24 h post MSN-FRB-VCs addition. Images were
acquired on an UltraVIEW VoX spinning dizc
system with laser line combiner (PerkinElmer)
assembled with an inverted microscope (Axio
Observer D1) using a 63x/1.4 NA Plan-
Apochromat oil immersion objective (Zeiss).
Images were acquired with an EMCCD camera
(C9100-50, Hamamatsu). The microscope was
equipped with a humidified and heated environ-
mental chamber set to 37 °C, 5% CO2 (PeCon).
Image acquisition was controlled by the program
Volocity (ver. 6.3, PerkinElmer).
Flow cytometry
Cells were washed with PBS, detached from a 6-
well plate using 0.25% Trypsin-EDTA and finally
re-suspended in PBS (3 mL per well) prior to flow
cytometry (FACS Aria II, BD Biosciences). Data
were analyzed using FlowJo (8.1) software. Non-
MSN treated HeLa-FKBP-VN-RFP cells were used
to gate out dead cells and aggregates and to cali-
brate appropriate Venus (using FITC settings) and
mRFP gating. Venus +ve and – ve cells were
analyzed from the RFP +ve group. 10,000 cells
were measured per sample. Experiments were tri-
plicated. Error bars represent standard deviations.
P values were obtained through application of
two-tailed T-tests with unequal variances.
Microplate reader for cell fluorescence readout
Cells were detached from a 6-well plate using
0.25% Trypsin-EDTA, harvested and washed with
PBS. After centrifugation (150 × g, 5 min), cells
were re-suspended in 100 µl of PBS and pipetted
into a 96-well microplate (Greiner Bio-One,
Germany). Fluorescence was measured using a
microplate reader (Infinite® M1000 PRO,
TECAN) with 515 nm excitation and 528 nm
emission for Venus measurements and 556 nm
excitation and 586 nm emission for RFP measure-
ments. Four readings were taken per well.
Background fluorescence in the Venus channel
was measured using the stable cell line without
addition of the complementing protein and sub-
tracted from other readings. Measurements were
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normalized against the RFP channel to account for
variations in cell number. Experiments were per-
formed in six biological repeats. Error bars repre-
sent standard deviations. P values were obtained
through application of two-tailed T-tests with
unequal variances.
MTT assay
One day prior to MTT assay HeLa Kyoto cells
were plated on a 96-well microplate (5 × 103 cells
per well) in DMEM and incubated at 37 °C. After
removal of culture medium, cells were exposed to
100 µl of MSN-DMEM solution per well (serum
free) with various concentrations, while the con-
trol group was incubated with 100 µl of serum-free
DMEM. Following 2 h incubation, the cells were
washed with PBS three times to remove the resi-
dual particles. Freshly prepared MTT solution
(0.5 mg/ml in DMEM) was added to the cells
(100 µl/well) and the cells were incubated at 37 °
C for another 4 h. The purple crystals metabolized
from healthy cells were then dissolved in 100 µl of
DMSO and the absorbance was measured at
570 nm, while the reference absorbance was mea-
sured at 655 nm using a microplate reader
(Infinite® M1000 PRO, TECAN). Experiments
were triplicated. Error bars represent standard
deviations. P values were obtained through appli-
cation of two-tailed T-tests with unequal variances.
Protein delivery rate experiments
Rapamycin-primed sample
HeLa-FKBP-VN-RFP cells were seeded onto a 2-
well ibi-Treat slide 12 h before the experiment. For
the rapamycin-primed protein release tracking
experiment, 1 µl of rapamycin (from 250 µM
stock solution) and 100 µg of MSN-FRB-VC
were mixed in 1 mL of serum-free DMEM, and
the mixture was added to the cells before the first
image was acquired. After 2 h, particles were
washed away using PBS, followed by a chloroquine
shock (0.5 mM of chloroquine in standard
DMEM, 1.5 mL/well) at RT for 5 min triggering
endosomal protein release. Cells were tracked at
indicated time points for 24 h. Microscopic images
were acquired with a Nikon TiE microscope
equipped with perfect focus, Yokogawa CSU-W1
spinning disk unit (50 µm pinhole size), Andor
ALC600 laser-beamcombiner: 405nm/488nm/
561nm/640nm, Yokogawa CSU-W1 dichroic mir-
ror 405/488/561/640 LD Quad, Andor Borealis
illumination unit and Andor IXON 888 Ultra
EMCCD camera using a Nikon CFI P-Apo 100x
Lambda oil immersion objective NA 1.45. The
setup was equipped with an environmental cham-
ber (Okolab BIO 1, Bold Line CO2 and tempera-
ture module, gas chamber and humidifying
module) and controlled by software from Nikon
(NIS elements, version 4.51.01). The environmen-
tal conditions during the experiment were set to 37
°C, 5 % CO2 and humidified atmosphere. Focus
drifts during the long-term experiments were
compensated by the Nikon perfect focus system.
Tiled images (10x10 image fields, 15 % overlap,
stitched by NIS elements) were acquired through-
out this study to investigate many cells per experi-
ment. 4 color tiles (488 nm, 561 nm, 640 nm and
differential interference contrast) were acquired
with a frequency of 3 images per hour. On chip
binning (2x2) was used throughout to reduce the
data amount and to improve the signal to noise
ratio. Fluorescence images were acquired with an
exposure time of 1 s and an EM gain setting of
160. For the population protein delivery tracking
analysis, a single large field area with 200 −300
cells was assessed at each interval.
Rapamycin-delayed sample
For the Venus reconstitution kinetics tracking
(rapamycin-delayed sample), 100 µg of MSN-
FRB-VC were mixed in 1 mL of serum-free
DMEM, and the mixture was added to the cells
before the first image was acquired. After 2 h,
particles were washed away using PBS, followed
by a chloroquine shock. Cells were tracked at
indicated time points using confocal microscopy
(an UltraVIEW Vox spinning dizc confocal sys-
tem, PerkinElmer, UK). Rapamycin (1 µl, final
conc. 250 nM in standard DMEM) was added to
the sample 22 h after chloroquine shock. Live
cell images were acquired at randomly chosen
areas to prevent Venus fluorescence bleaching.
200 – 300 cells were imaged and counted at
each time point. Venus positive cells were
counted visually. Venus positive cells in % cor-
respond to the number of nuclei with Venus
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fluorescence divided by the number of cells with
RFP fluorescence * 100.
Single cell fluorescence tracking
Tracking of fluorescent intensity within single cells
was performed on images acquired using a Nikon
TiE microscope utilized as outlined above.
Rapamycin-primed (250 nM rapamycin applied
with MSNs) and delayed experiments (250 nM
rapamycin added 24 hs after MSNs) were per-
formed. Fiji software was used to analyze images.
A circular ROI of consistent size was used to
measure fluorescence in cell nuclei. The ROI was
positioned in the nucleoplasm excluding the dar-
ker nucleoli. Measurements were taken until mito-
sis of the cell occurred or imaging ended.
Results
To develop a controllable BiFC sensor we used the
chemically inducible dimerization (CID) compo-
nents FKBP/FRB[38] that form a heterodimer in
the presence of rapamycin[39]. For BiFC we
selected the split Venus fluorescent protein (split
154/155) based on its high fluorescence signal,
rapid maturation at 37 °C and low auto-comple-
mentation[40,41]. Our overall approach is outlined
in Figure 1. In brief, we fused the N-terminal
portion of Venus (VN) with FKBP and added a
c-Myc nuclear localization signal (NLS)[42] to
facilitate subsequent image analyses (Figure 1(a)).
For expression control and calibration we added
an mRFP which follows a T2A peptide[43]. The
T2A induces ribosomal skipping which enables the
synthesis of two proteins (FKBP-VN and mRFP)
from one transcript. A blasticidin resistance gene
was included to assist in the selection and main-
tenance of a monoclonal stable cell line (HeLa-
FKBP-VN), which was used for all subsequent
studies. The complementary half of the BiFC/CID
complex (Figure 1(b)), consisting of a His-tagged
FRB domain fused to the C-terminal half of Venus
(VC), was bacterially expressed, purified by affinity
chromatography and loaded into the MSNs for
cellular delivery (Figure 1(c)).
Following endocytosis of FRB-VC loaded MSNs
(MSN-FRB-VC)[44], carrier and cargo proceed
through the endosomal system where decreasing
pH causes dissociation of His-tagged FRB-VC
from the MSN. Endosomal rupture is triggered
using chloroquine[19] and FRB-VC is released to
the cytosol. FRB-VC diffuses to the nucleus and
interacts with FKBP-VN, which is primed for
dimerization with pre-bound rapamycin. This
ternary complex formation (FKBP-rapamycin-
FRB) approximates the two Venus halves, pro-
motes complementation and enables chromophore
maturation. Thus, successful protein delivery can
then be monitored as Venus fluorescence in the
nucleus, which concentrates the signal, facilitates
automated image analysis and improves the signal
to noise ratio.
Large-pore MSNs were surface-functionalized
with NTA-Ni complexes (MSN-Ni) through a ser-
ies of modifications (Figure 2(a)) to accommodate
pH dependent binding and release of the His-
tagged FRB-VC[10,11,19]. STEM and SEM images
(Figure 2(b)) indicated that the resulting nitrilo-
triacetic acid-modified MSNs (MSN-NTAs) exhi-
bit uniform particle size and coral surface
morphology with irregular pore shape (pore size
ranging from 10 – 40 nm) consistent with the
structure of the un-functionalized form
(Figure S1). These particle characteristics were
confirmed by dynamic light scattering (DLS)
(Figure 2(c)) and N2 sorption analyses (Figures 2
(d,e)) and are summarized in Table S1.
To optimize protein delivery we first tested differ-
ent particle concentrations. As expected, the HeLa-
FKBP-VN cell line by itself and the addition of
unloaded MSNs did not yield any Venus fluores-
cence while MSN-FRB-VC complexes led to clear
nuclear signals (Figure 3(a), Figure S2). Successful
protein delivery can be conveniently quantified in
cell populations with microplate fluorometry, as the
formation of Venus fluorescence requires endosomal
escape and release of functional proteins. Whilst a
significant increase (p = 0.004) in protein delivery is
seen between the 50 µg/ml and 100 µg/ml concen-
trations, the fluorescent signal plateaued at higher
concentrations (Figure 3(b)). We then measured
protein transfection rates, i.e. the fraction of cells
with a clear fluorescence signal, by flow cytometry
and again found a significant increase from 50 µg/ml
to 100 µg/ml concentrations (p = 0.016) indicating
some dose dependency, with higher concentrations
having no further positive effect (Figure 3(c)). MTT
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assays were performed in parallel to assess possible
cytotoxicity. Results indicated that nanoparticle
additions up to 100 µg/ml did not affect cell viability.
However, increased cytotoxicity was observed with
higher particle concentrations of 150 µg/ml and
200 µg/ml (Figure 3(d)). Based on these three data
sets, we selected 100 µg/ml as the optimal MSN
concentration to obtain high protein delivery effi-
ciency with low cytotoxicity.
To monitor protein delivery in single cells, we
imaged live cell populations with spinning dizc
microscopy over time. We first incubated rapa-
mycin primed HeLa-FKBP-VN cells with MSN-
FRB-VC complexes (100 µg/ml) and imaged
before and after chloroquine shock. While no
Venus fluorescence was detected before the
chloroquine shock, first signals became visible
in nuclei of about 1% of the cells within
30 min after chloroquine mediated endosome
rupture, surpassed 50% after 5.5 h and reached
85% at 9 h (Figure 4(a)). A live cell image of
protein release taken 10 h post chloroquine
shock shows yellow fluorescent nuclei, i.e. suc-
cessful protein delivery, in most cells (Figure 4
(c)). Time-lapse videos covering the entire time
course of protein delivery into hundreds of cells
show this cell-to-cell temporal variability of
nuclear fluorescence onset over 24 h (movie 1).
Figure 1. A two-component protein delivery sensor. Layouts of the: a mammalian expression cassette and b bacterial expression
cassette are shown. c MSN-mediated protein delivery sensing. 1 His-tagged FRB-VC proteins are loaded into MSNs via surface Ni-NTA
complexes. 2 Charged MSN-FRB-VCs bind to HeLa-FKBP-VN cell surfaces and are 3 endocytosed. Lower pH in the endosomal system
causes accelerated FRB-VC dissociation from the MSN. 4 Chloroquine shock triggers endosomal protein release followed by 5 free
diffusion of FRB-VCs into the nucleus. 6 Addition of rapamycin leads to the formation of FRB/rapamycin/FKBP ternary complexes
driving Venus complementation and fluorophore maturation.
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To address this cell-to-cell temporal variability
we incubated cells with MSN-FRB-VC and added
rapamycin (250 nM) 22 h after chloroquine shock
(Figure 4(b)). We reasoned that at this point the
protein was likely already released in the majority
of the cells and therefore the timing of Venus
fluorescence should represent sensor complex for-
mation and maturation rather than protein release.
The comparison of both experimental conditions
shows that while in rapamycin primed cell popula-
tions the onset of nuclear fluorescence occurred
over a period of 10 hours, the later addition of
rapamycin caused a synchronous onset within
1–2 h within the majority of cells monitored by
live cell microscopy (Figures 4(a,b)). Also, the
quantification of fluorescence in single cells over
time shows the heterogeneity in fluorescence
increase in the rapamycin primed cells as opposed
to the synchronous increase of fluorescence in the
cells with delayed rapamycin addition (Figures 4
(d,e)). The heterogeneous fluorescence onset and
increase in the rapamycin primed cells suggests
Figure 2. Synthesis and characterization of MSNs for controlled binding and release of His-tagged protein. a Surface modification
series of un-functionalized MSNs (un-MSNs) to MSN-Ni. b STEM (left) and SEM (right) images of MSN-NTAs, scale bar: 50 nm.
Characterization of un-MSNs and MSN-NTAs: c dynamic light scattering, d N2 sorption isotherms and e pore size distribution
calculated via NLDFT mode.
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that endosomal rupture may continuously occur
even several hours after transient chloroquine
shock. Consistently, we observe enlarged endo-
somes even 15 h after chloroquine shock indicat-
ing prolonged endosomal rupture over many
hours (Figure S3). Unlike sensors that rely upon
transcription or other amplification mechanisms,
the ratio-metric nature of the BiFC sensor enables
cell-to-cell variation measurements not only
between but also within populations (Figure 4(f)).
With image analysis, parameters such as the range
of protein released within a cell population as well
as means and standard deviations can be deter-
mined. Clearly, the combination of protein deliv-
ery with subsequent activation methods, like the
bimolecular complementation triggered here by
rapamycin, provides a defined starting point for
functional studies.
Discussion
The BiFC sensor described in this study makes it
possible to simultaneously monitor the time
course of protein delivery and cellular responses
in thousands of cells over hours and days. The lack
of any signal amplification mechanism limits the
maximal sensitivity of the BiFC sensor, but due to
its ratio-metric nature enables cell-to-cell variation
measurements. In consideration of the significance
of cellular protein stoichiometry this should be a
Figure 3. Optimization of MSN-mediated protein delivery. Different MSN-FRB-VC concentrations were incubated with HeLa-FKBP-VN
cells. a Live-cell images were taken 20 h post endosomal protein release induction. Scale bar: 10 µm. b Population fluorescence was
measured using a microplate reader. c Flow cytometry measured protein transfection rate. d MTT assays assessed cytotoxicity of un-
MSNs. Error bars represent SDs.
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useful attribute for understanding and adapting
nanocarriers for various tasks.
Fluorescent live cell delivery tracking
revealed a variable timing of bioavailability
upon addition of MSNs, indicating that cellular
uptake and intracellular release of functional
proteins varies from cell to cell by several
hours. This temporal heterogeneity in direct
protein delivery experiments complicates
functional studies. One possible solution is pro-
tein splitting and addition of controllable
dimerization modules that allows for delivery
of inactive protein halves over longer time
intervals and subsequent activation by chemical
induction across cell populations. Our results
show that the delivery of inactive protein halves
in combination with the chemically inducible
dimerization components FKBP/FRB allow for
Figure 4. Live cell tracking of protein release. a MSN-FRB-VCs were added to rapamycin primed HeLa-FKBP-VN cells at time point
−2 h and live cell imaging began. Following chloroquine shock at 0 h cells were imaged and analyzed for Venus nuclear fluorescence
rates for a further 12 h. b MSN-FRB-VCs and chloroquine were applied as above. Delayed rapamycin addition (22 h after chloroquine
shock) triggered synchronous activation of delivered protein, cell imaging and analysis of Venus fluorescence continued for 5 h. c A
live cell image of the rapamycin-primed sample 10 h after chloroquine shock. Scale bar: 100 µm. Fluorescence intensity tracking from
30 cells in d rapamycin-primed and e rapamycin-delayed samples. f Fluorescence intensity distribution among 625 cells in a
rapamycin-primed sample analyzed at 15 h post chloroquine shock.
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rapamycin triggered functional complementa-
tion and thus provide a defined starting point
for functional studies and enable the controlled
manipulation of cellular functions.
The focus of this study was on the delivery
process and therefore only one half of the split
protein was delivered and the other half was
produced by genetic means in the recipient
cells, but as single MSNs can carry multiple
molecules and single cells can uptake multiple
MSNs, also mixtures of proteins can be deliv-
ered. To be able to quantify the rate and effi-
ciency of delivery we used a split fluorescent
protein (Venus) which is only one of a rapidly
growing list of proteins that can be split and
then functionally complemented. Therefore, this
approach could easily be extended to a large
number of proteins through either trial and
error or based on structural information and
should be applicable to single globular domains
as well as multidomain proteins [45,46].
Conclusions
In summary, we have developed an inducible two-
component fluorescent live cell sensor to track and
optimize protein delivery with respect to effi-
ciency, bioavailability and biocompatibility. We
propose that the system described here is well
suited for multi-parameter optimization and the
comparison of different protein nanocarriers. We
demonstrate that large pore MSN-Nis are capable
of non-toxic nuclear delivery in up to 80% of a cell
population whilst requiring only a his-tag for pro-
tein loading. In light of these properties as well as
the prevalent use of his-tags for protein purifica-
tion we suggest that MSN-Nis are good candidates
for widespread cell research use. Finally, we have
shown that small molecule controlled bimolecular
complementation can be used for synchronous
activation of delivered proteins in cell populations
and provide a defined start point for functional
studies.
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